JNJ vs. Eli Lilly: FY 2025 Financial Performance and Growth

Evaluating the fiscal year 2025 performance of major pharmaceutical operators highlights contrasting operational models between established enterprise stability and rapid sector expansion.

### Session Tape — Johnson & Johnson ($JNJ+WL -2.30%), Eli Lilly & Co (LLY -0.63%)

## Catalyst Analysis: FY 2025 Financials and Portfolio Metrics Johnson & Johnson operates through innovative medicine and diverse medical device segments, reaching a global audience of hospitals and wholesalers while collaborating with partners like AbbVie (ABBV -0.64%) on oncology treatments. In fiscal year 2025, revenue reached roughly $94 billion, marking a 6% increase from the prior period, paired with a net income of nearly $27 billion and a net margin of approximately 29%. Operating cash flow minus capital expenditures reached nearly $19.7 billion.

Conversely, Eli Lilly demonstrated aggressive expansion, driven heavily by metabolic products that generated roughly 82% of its revenue in 2025. Revenue reached about $65.2 billion, representing a 45% growth rate compared to the prior year, translating into a net income of approximately $20.6 billion and a net margin of nearly 32%. Wholesale distributors such as McKesson Corp (MCK +5.27%), Cencora Corp (COR +3.17%), and Cardinal Health Inc (CAH +3.65%) continue to facilitate broad distribution channels across third-party pharmacies.

## Impact on Related Tickers Sector participants including AbbVie, McKesson, Cencora, and Cardinal Health reflect broader supply chain and co-commercialization dynamics across healthcare markets.